Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia

International Journal of Hematology

Volumn 63, Issue 1, 1996, Pages 19-23

  Usuki, Kensuke ^a   Endo, Mitsue ^a   Osawa, Mayumi ^a   Kitazume, Koichi ^a   Iki, Seiko ^a   Urabe, Akio ^a,b  

^a NTT Medical Center Tokyo   (Japan)

^b NONE   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Bioavailability; Food; Pharmacokinetics

Indexed keywords

DAUNORUBICIN; ENOCITABINE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BIOAVAILABILITY; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; NUTRITION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030039464     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/0925-5710(95)00416-5     Document Type: Article

References (22)

1. Grignani F, Fagioli M, Alcalay M et al. Acute promyelocytic leukemia: From genetics to treatment. Blood 1994;83:10-25.
2. Kanamaru A, Takemoto Y, Tanimoto M et al. All-trans-retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995;85;1202-1206.
3. Frankel SR, Eardley A, Heller G et al. All-trans-retinoic acid for acute promyelocytic leukemia: Results of the New York study. Ann Intern Med 1994;120:278-286.
4. Fenaux P, Le Deley MC, Castaigne S et al. Effect of all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood 1993;82:3241-3249.
5. Warrell Jr RP. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 1993;82:1949-1953.
6. Li Y-P, Said F, Gallagher RE. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-α. Blood 1994;83:3298-3302.
7. Robertson KA, Emami B, Collins SJ. Retinoic acid resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992;80:1885-1889.
8. Ruchaud S, Duprez E, Gendron MC et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Pro Natl Acad Sci USA 1994;91:8428-8432.
9. Dermime S, Grignani F, Clerici M et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. Blood 1993;82: 1573-1577.
10. Comic M, Delva L, Castaigne S et al. In vitro all-trans-retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994;8:914-917.
11. Comic M, Delva L, Guidez F et al. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992;52:3329-3334.
12. Delva L, Cornic M, Balitrand N et al. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993;82:2175-2181.
13. Muindi J, Frankel SR, Miller WH et al. Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 1992;79:299-303.
14. Huang M, Ye Y, Chen S et al. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.
15. Colburn WA, Gibson DM, Rodriguez LC, Bugge CJL, Blumenthal HP. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1985;25:583-589.
16. Colburn WA, Gibson DM, Weins RE and Hanigan JJ. Effect of meals on the kinetics of etretinate. J Clin Pharmacol 1983;23:534-539.
17. Lo Coco F, Diverio D, Pandolfi PP et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992;340: 1437-1438.
18. Frankel SR, Eardley A, Lauwers G et al. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-296.
19. Fenaux P, Castaigne S, Dombret H et al. All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992;80:2176-2181.
20. Lefebvre P, Thomas G, Gourmel B, Agadir A, Castaigne S. and Dreux C. Pharmacokinetics of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia. Leukemia 1991;5:1054-1058.
21. Muindi RF, Frankel SR, Huselton C et al. Clinical pharmacology of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992;52: 2139-2142.
22. 2) in acute promyelocytic leukemia. Blood 1993;82:3560-3563.